News coverage about Cutera (NASDAQ:CUTR) has trended somewhat negative recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cutera earned a daily sentiment score of -0.02 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Comparing Lumenis (LMNS) & Cutera (CUTR) (americanbankingnews.com)
- Reviewing Lumenis (LMNS) & Cutera (CUTR) (americanbankingnews.com)
- Contrasting Cutera (CUTR) & Lumenis (LMNS) (americanbankingnews.com)
- Cutera, Inc. (CUTR) Given Average Rating of “Strong Buy” by Analysts (americanbankingnews.com)
- Insider Selling: Cutera, Inc. (CUTR) EVP Sells 2,563 Shares of Stock (americanbankingnews.com)
Several brokerages have recently commented on CUTR. Sidoti reaffirmed a “buy” rating and set a $30.00 target price (up from $27.00) on shares of Cutera in a report on Saturday, June 3rd. Zacks Investment Research lowered Cutera from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. Finally, TheStreet lowered Cutera from a “b-” rating to a “c” rating in a research report on Monday, May 1st.
Shares of Cutera (CUTR) traded down 4.41% on Tuesday, reaching $23.85. The company’s stock had a trading volume of 117,067 shares. The company’s 50 day moving average is $21.83 and its 200-day moving average is $19.91. Cutera has a 1-year low of $10.42 and a 1-year high of $24.95. The stock has a market cap of $330.51 million, a PE ratio of 91.38 and a beta of 0.62.
Cutera (NASDAQ:CUTR) last posted its quarterly earnings results on Monday, May 1st. The medical device company reported ($0.07) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). The company had revenue of $29.30 million for the quarter, compared to the consensus estimate of $29 million. Cutera had a net margin of 2.89% and a return on equity of 9.21%. The firm’s revenue was up 30.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.16) EPS. On average, equities analysts predict that Cutera will post $0.47 earnings per share for the current fiscal year.
In other Cutera news, CFO Ronald J. Santilli sold 20,856 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $19.90, for a total transaction of $415,034.40. Following the transaction, the chief financial officer now owns 92,178 shares of the company’s stock, valued at approximately $1,834,342.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Larry Laber sold 2,563 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $24.36, for a total transaction of $62,434.68. Following the transaction, the executive vice president now directly owns 74,203 shares in the company, valued at approximately $1,807,585.08. The disclosure for this sale can be found here. Insiders sold a total of 158,910 shares of company stock worth $3,324,504 in the last ninety days. 3.30% of the stock is currently owned by insiders.
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.